Prophylactic argon laser coagulation for rhegmatogenous retinal detachment in AIDS patients with cytomegalovirus retinitis.
BACKGROUND
The incidence of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) reaches 20-45%. Despite aggressive medical treatment, rhegmatogenous retinal detachments develop in up to 30% of the affected eyes. Surgical repair is often difficult due to multiple large and hardly visible retinal holes with vitreal traction. Pars plana vitrectomy with instillation of silicone oil is the procedure of choice, giving limited functional results with anatomical reattachment.


METHODS
We performed prophylactic laser coagulation in AIDS patients with medically treated CMV retinitis to prevent a progressive retinal detachment. Twenty-two quiescent CMV lesions in 22 eyes of 20 patients were treated with argon green laser coagulation. Each CMV lesion was completely surrounded with a double or triple row of laser spots (500-600 mumols; 0.2 s; gray-white lesions).


RESULTS
The duration of follow-up was 2-24 months. Histopathologic evaluation was possible in two eyes of one patient. Reactivated or smoldering CMV retinitis crossed the laser scars in 11 eyes, making additional laser coagulation necessary. In four eyes retinal holes in the CMV scar tissue led to retinal detachment, which stopped at the laser scar. In three eyes the detachment is still controlled by the laser scar. In one eye, the detachment stopped at the laser scar for 6.5 months and then slowly progressed across it. There were no complications associated with our laser treatment.


CONCLUSIONS
Prophylactic argon laser coagulation in quiescent CMV retinitis seems to reduce the rate of progressive retinal detachment with no need for vitrectomy and silicone oil tamponade.
Althaus
C
C
University Eye Hospital, Heinrich Heine University, Düsseldorf, Germany.
Loeffler
K U
KU
Schimkat
M
M
Hudde
T
T
Sundmacher
R
R
D017088:AIDS-Related Opportunistic Infections / Q000150:complications* / Q000188:drug therapy; D000998:Antiviral Agents / Q000627:therapeutic use; D017726:Cytomegalovirus Retinitis / Q000150:complications* / Q000188:drug therapy; D017245:Foscarnet / Q000627:therapeutic use; D005654:Fundus Oculi; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D017075:Laser Coagulation; D012160:Retina / Q000601:surgery; D012163:Retinal Detachment / Q000209:etiology / Q000517:prevention & control* / Q000601:surgery; D012167:Retinal Perforations / Q000209:etiology
D000998:Antiviral Agents; D017245:Foscarnet; D015774:Ganciclovir